A Phase 1b clinical trial is an open-label, single and multiple-dose escalation study of TU7710
Latest Information Update: 28 Mar 2024
At a glance
- Drugs NBP 604 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
Most Recent Events
- 28 Mar 2024 New trial record
- 26 Mar 2024 According to a TiumBio media release, the company has filed a Clinical Trial Application (CTA) with the Italian Medicines Agency (AIFA) and the Spanish Agency of Medicines and Medical Products (AEMPS) to initiate a Phase 1b study with the TU7710. The trial will enroll up to 18 hemophilia A or B patients with inhibitors and will be conducted in Italy and Spain.